These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38897866)

  • 21. Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.
    Shibaki R; Murakami S; Shinno Y; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Yamamoto N; Ohe Y
    Cancer Immunol Immunother; 2020 Jul; 69(7):1229-1236. PubMed ID: 32152703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
    Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
    Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?
    Lai HC; Lin JF; Hwang TIS; Liu YF; Yang AH; Wu CK
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31058839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.
    Di Lorenzo G; De Placido S; Pagliuca M; Ferro M; Lucarelli G; Rossetti S; Bosso D; Puglia L; Pignataro P; Ascione I; De Cobelli O; Caraglia M; Aieta M; Terracciano D; Facchini G; Buonerba C; Sonpavde G
    Expert Opin Biol Ther; 2016 Nov; 16(11):1387-1401. PubMed ID: 27463642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network Meta-Analysis.
    Chu X; Tian W; Ning J; Zhou R
    J Natl Cancer Inst; 2024 Jun; ():. PubMed ID: 38885371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
    Kammerer-Jacquet SF; Crouzet L; Brunot A; Dagher J; Pladys A; Edeline J; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Patard JJ; Lespagnol A; Mosser J; Denis M; Messai Y; Gad-Lapiteau S; Chouaib S; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
    Int J Cancer; 2017 Jan; 140(1):142-148. PubMed ID: 27623354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
    Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
    Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.
    Niu M; Yi M; Wu Y; Lyu L; He Q; Yang R; Zeng L; Shi J; Zhang J; Zhou P; Zhang T; Mei Q; Chu Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):94. PubMed ID: 37573354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
    Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma.
    Aoki T; Kudo M; Ueshima K; Morita M; Chishina H; Takita M; Hagiwara S; Ida H; Minami Y; Tsurusaki M; Nishida N
    Liver Cancer; 2024 Feb; 13(1):56-69. PubMed ID: 38344443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Targets in Clear Cell Renal Cell Carcinoma.
    Chen YW; Rini BI; Beckermann KE
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
    Atkins MB; Tannir NM
    Cancer Treat Rev; 2018 Nov; 70():127-137. PubMed ID: 30173085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma.
    Liu Y; Zhang Z; Liu R; Wei W; Zhang Z; Mai L; Guo S; Han H; Zhou F; He L; Dong P
    Radiat Oncol; 2021 Nov; 16(1):211. PubMed ID: 34727963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment.
    Hua Y; Dong R; Jin T; Jin Q; Chen X
    Front Oncol; 2022; 12():781348. PubMed ID: 35280787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clear Cell Renal Cell Carcinoma: From Biology to Treatment.
    Kase AM; George DJ; Ramalingam S
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.
    Montemagno C; Durivault J; Gastaldi C; Dufies M; Vial V; He X; Ambrosetti D; Kamenskaya A; Negrier S; Bernhard JC; Borchiellini D; Cao Y; Pagès G
    Mol Oncol; 2023 Jul; 17(7):1379-1401. PubMed ID: 36810959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients.
    Tozuka T; Yanagitani N; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Ariyasu R; Uchibori K; Kitazono S; Seike M; Gemma A; Nishio M
    Cancer Treat Res Commun; 2020; 25():100249. PubMed ID: 33249211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
    Alhalabi O; Thouvenin J; Négrier S; Vano YA; Campedel L; Hasanov E; Bakouny Z; Hahn AW; Bilen MA; Msaouel P; Choueiri TK; Viswanathan SR; Sircar K; Albiges L; Malouf GG; Tannir NM
    Oncologist; 2023 May; 28(5):433-439. PubMed ID: 36640141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
    Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
    Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.